Main Article Content
Background. Metformin is one of the most prescribed hypoglycemic drugs of the first line of treatment for patients with type 2 diabetes (T2D). However, the mechanism of its therapeutic effect has not been sufficiently studied. At the same time, T2D is considered a disease of an inflammatory nature, wherein different immune responses are disturbed. However, only single articles are devoted to the role of the immune system in the mechanism of the therapeutic action of metformin. Purpose of the study. Elucidation of the question to what extent different types of leukocytes, immunophenotype of lymphocytes and some cytokines are involved in the mechanism of the therapeutic action of metformin. Materials and methods. A group of patients of both sexes with a newly diagnosed T2D with BMI of 33.1 ± 1.3 kg/m2 who had not yet taken hypoglycemic agents and a group of normoglycemic healthy individuals of the same age and sex were examined. The number of leukocytes in blood was determined using the hematological analyzers, and the leukocyte composition — in Pappenheim stained smears. Immunophenotype of lymphocytes (CD3+ T, CD4+ T, CD8+ T, CD56+) — by flow cytometry using the FACStar plus cytofluorimeter. The content of different cytokines (I-1b, TNF-a and IL-10) — with immunosorbent ELISA assay. Results. The metformin therapy of newly diagnosed T2D patients with obesity leads to normalization of the increased number of leukocytes, neutrophils and monocytes, as well as a decrease in CD4+ T cells in the blood, especially in patients with high BMI. A characteristic feature of the therapy is a sharp decrease in anti-inflammatory cytokines (IL-1b and TNF-a) that were elevated before treatment. The obtained data indicate significant disorders of natural and adaptive immunity in T2D and confirm the hypothesis about the inflammatory nature of this disease. Conclusions. The favorable therapeutic effect of metformin in T2D, especially complicated by obesity, is largely due to the normalization of inflammation and immunity indices.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism. 2004 Feb;53(2):159-64. PMID: 14767866.
Baig S, Rizi EP, Shabeer M, et al. Acute meal challenge and modulation of postprandial immune-metabolic response in peripheral blood mononuclear cells, in lean, insulin-sensitive and obese, insulin-resistant Chinese. Diabetes. 2015;64(1):467.
Bouter KP, Meyling FH, Hoekstra JB, Masurel N, Erkelens DW, Diepersloot RJ. Influence of blood glucose levels on peripheral lymphocytes in patients with diabetes mellitus. Diabetes Res. 1992 Feb;19(2):77-80. PMID: 1286542.
Brooks-Worrell BM, Palmer JP. Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol. 2013 Feb; 171(2): 164–70. doi: 10.1111/cei.12012
Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016 Feb;39(2):198-205. doi: 10.2337/dc15-0488.
Сhe TT, Ren Y, Liu SF. Expression of circulating CD4+CD25+ FOXP3+ regulatory T cells in obese patients. Diabetologia. 2013;56(1):563.
Coppola A, Caputo MP, Pastore D, et al. Metformin inhibits leptin release induced by HMGB1 and exerts an anti-inflammatory action reducing TLR4/2 expression in T2D subjects. Diabetes. 2015;64(1):1830.
De la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care. 2017 Jan;40(1):54-62. doi: 10.2337/dc16-1324.
Fabbrini E, Cella M, McCartney SA, et al. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology. 2013 Aug;145(2):366-74.e1-3. doi: 10.1053/j.gastro.2013.04.010.
Hong SJ, Kim ST, Kim TJ, et al. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2655-65. doi: 10.1161/ATVBAHA.110.212670.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413.
Konopka AR, Esponda RR, Robinson MM, et al. Hyperglucagonemia mitigates the effect of metformin on glucose production in prediabetes. Cell Rep. 2016 May 17;15(7):1394-1400. doi: 10.1016/j.celrep.2016.04.024.
Kűhtreiber WM, Burger D, Reinhold III PE. et al. Heterogeneity in type 1 diabetics is defined by contrasting C-peptide declines, autoreactive T cell burdens, and metabolic differences. Diabetes. 2015;64(4):1105-7.
Kullo IJ, Hensrud DD, Allison TG. Comparison of numbers of circulating blood monocytes in men grouped by body mass index (<25, 25 to <30, > or =30). Am J Cardiol. 2002 Jun 15;89(12):1441-3. PMID: 12062747.
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011 Mar;13(3):221-8. doi: 10.1111/j.1463-1326.2010.01349.x.
Luo T, Nocon A, Fry J. et al. AMPK activation by metformin suppresses abnormal extracellular matrix remodelling in adipose tissue and ameliorates insulin resistance in obesity. Diabetes. 2016 Aug;65(8):2295-310. doi: 10.2337/db15-1122. Epub 2016 May 13.
Mulherin AJ1, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology. 2011 Dec;152(12):4610-9. doi: 10.1210/en.2011-1485.
O’Rourke RW, White AE, Metcalf MD, et al. Hypoxia-induced inflammatory cytokine secretion in human adipose tissue stromovascular cells. Diabetologia. 2011 Jun;54(6):1480-90. doi: 10.1007/s00125-011-2103-y.
Orlenko VL, Zak KP. Treatment with Glucagon-Like Peptide-1 Analogues — a Breakthrough in Diabetes Mellitus Type 2 Therapy. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2014;4(60):112-7. doi:10.22141/2224-07188.8.131.524.76690. (in Russian).
Pham MN, Hawa MI, Pfleger C, et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia. 2011 Jul;54(7):1630-8. doi: 10.1007/s00125-011-2088-6.
Saienko YaA, Zak KP, Popova VV, Semionova TA. Leukocyte Composition and Immunophenotype of the Blood Lymphocytes in Women with Type 2 Diabetes Mellitus and Obesity. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2016;5(77):13-9. doi:10.22141/2224-07184.108.40.2066.78748. (in Russian).
Schipper HS, Nuboer R, Prop S, et al. Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14++ monocytes. Diabetologia. 2012 Oct;55(10):2800-2810. doi: 10.1007/s00125-012-2641-y.
Seyhan A, Nunes-Lopez Yu, Garufi G. Differences in serum cytokine concentration in lean and obese individuals with prediabetes and type 2 diabetes. Diabetes. 2015;64(1):472.
Simmons RK, Alberti KG, Gale EAM, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010 Apr;53(4):600-5. doi: 10.1007/s00125-009-1620-4.
Wang Q, Zhang M, Torres G. et al. Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission. Diabetes. 2017 Jan;66(1):193-205. doi: 10.2337/db16-0915.
Zak KP, Popova VV. The Prediction of Type 1 Diabetes Development and Diagnosis of Its Asymptomatic Phase Using Autoantibodies to Human Islets of Langerhans Long Before the Onset of the Disease. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2016;7(79):11-21. doi:10.22141/2224-07220.127.116.116.86414. (in Russian).
Zak KP. The Role of Neutrophilic Leukocytes in the Pathogenesis of Human Type 1 Diabetes (Analytical Review with the Inclusion of Our Own Data). Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2016;2(74):130-9. doi: 10.22141/2224-0718.104.22.1686.70956 . (in Russian).